The aim of our study was to evaluate the impact of an early intensification programme including chemotherapy (CHT), autologous stem cell transplantation (ASCT) and radiation therapy (RT) in patients with primary mediastinal large B cell lymphoma (MLCL) with sclerosis presenting with adverse prognostic factors. Between 1993 and 1999, 19 patients with MLCL were referred to our institution. Four patients were classified as low risk according to the age-adjusted International Prognostic Index (AA-IPI). Fifteen (79%) were categorised in the high-intermediate or high risk group and were considered eligible for ASCT. Induction therapy consisted of VACOP-B (etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone and bleomycin) for 12 weeks. After induction therapy the four low risk patients achieved a complete remission (CR) and did not undergo ASCT. Of the 15 poor risk patients, five achieved CR, seven partial remission (PR), and three showed refractory disease (RD). All these patients received mobilising therapy consisting of high-dose cyclophosphamide. After peripheral stem cell (PSC) collection, to obtain a greater tumor mass reduction before transplantation, the seven patients in PR underwent further treatment with high-dose etoposide and those with RD received two cycles of DHAP (dexamethasone, cytarabine and cisplatin). At the time of ASCT, seven patients were in CR, six in PR and two had RD. After transplantation using BEAM as preparative regimen, all patients but one achieved a CR. Seven patients with minimal (Ͻ25%) residual mass at computed tomography scan received further mediastinal RT even if they had a negative Ga 67 scan. At a median follow-up of 35 months from transplantation the disease free survival is 93%. The outcome following this programme of early intensification in poor prognosis MLCL results in a high
Primary mediastinal (thymic) large B cell lymphoma (MLCL) with sclerosis has emerged in recent years as a distinct clinico-pathologic entity, and in 1994 it was recognised in the Revised European-American Lymphoma (REAL) classification as a separate entity. 1 This disease is characterised by extremely rapid growth, is usually bulky, and often invades contiguous thoracic structures in the absence of generalised adenopathy. Most early publications suggested that mediastinal large cell lymphomas were aggressive disorders resistant to treatment even with the otherwise effective combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), and carried a poorer prognosis than other large cell lymphomas. 2, 3 These results have been contradicted by more recent studies: CR rates of 53 to 89% have been reported after initial therapy, usually followed by consolidation radiotherapy, with an overall survival rate at 5 years of 50 to 65%. [4] [5] [6] [7] [8] However, patients with an incomplete response to initial chemotherapy or with primarily refractory disease are often resistant to chemo-radiotherapy salvage and are characterised by a poor outcome. 5, 6 Treatment intensification with high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has been successfully used in aggressive non-Hodgkin's lymphoma patients with poor prognostic features and as salvage treatment for patients with refractory disease. [9] [10] [11] [12] Durable responses and a high rate of cure have also been observed after ASCT in patients with poor prognosis recurrent or refractory mediastinal large cell lymphoma. [12] [13] [14] In the setting of large cell lymphomas the GELA (Groupe d'Etude des Lymphomes de l'Adulte) study clearly demonstrated that patients with high, high-intermediate risk disease according to AA-IPI had a poor out-come when treated with conventional chemotherapy, but had survivals significantly improved by high-dose therapy and ASCT. [15] [16] [17] The aim of our study was to evaluate the role of an early intensification treatment integrating induction CHT, ASCT and RT in patients with primary MLCL with sclerosis presenting with adverse prognostic factors.
Patients and methods
Between August 1993 and November 1999, 19 consecutive patients with a confirmed histologic diagnosis of primary MLCL Lymphoma with sclerosis (according to the REAL classification 1 ) were referred to our institution. Histology specimens were obtained through thoracotomy or supraclavicular lymph node biopsies in 15 and four cases, respectively. Clinical staging included physical examination, haematological and biochemical laboratory tests, bone marrow biopsy, total body computed tomography, echocardiogram and Ga 67 scan; the latter was routinely performed at diagnosis and after treatment. All patients were clinically staged according to the Ann Arbor classification and stratified among the four risk groups of the AA-IPI. 15, 18 Characteristics at presentation of the 19 patients, five men and 14 woman, are shown in Table 1 . The median age at diagnosis was 30 years (range 16 to 52 years). Eighteen patients (95%) presented with bulky mediastinal disease (defined as a mass more than 10 cm in diameter); 11 (58%) had an elevated serum LDH level; pleural and/or pericardial 
Criteria of response
Complete remission (CR) was defined as complete disappearance of all measurable disease. Patients with a tumour mass reduction on CT scan of greater than 75% with Ga 67 scan negativity were considered to be in CR. Partial remission (PR) was defined as greater than 50% to 75% reduction of tumour mass. 19 Refractory disease (RD) was defined as a tumour mass reduction of less than 50%, or transient disease regression lasting less than 1 month. 20 
Treatment
All patients received etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone and bleomycin (VACOP-B) as first-line treatment. 21 Patients in the high-intermediate or high risk group according to the AA-IPI score were considered eligible for mobilising chemotherapy and ASCT. Mobilising therapy consisted of 4 g/m 2 of cyclophosphamide followed by G-CSF at a dose of 300 g/day for patients in CR after front-line treatment; in patients not achieving CR after VACOP-B, the dosage of cyclophosphamide was increased to 7 g/m 2 . To reach the target quantity of 5 × 10 6 CD34 + cell/kg one or two leukaphereses were performed.
To further reduce the tumour burden before ASCT, patients in PR at the evaluation performed after mobilising treatment received an additional course of high-dose etoposide (2 g/m 2 ), while those with RD received two courses of DHAP. 22 The preparative regimen (BEAM protocol) consisted of: carmustine 300 mg/m 2 , day 1; etoposide 200 mg/m 2 daily and cytarabine 200 mg/m 2 twice daily, on days 2-5; melphalan 140 mg/m 2 , day 6. 23 The autologous stem cells were infused 48 h later, nominally on day 0 of ASCT, at doses ranging from 5.6 to 19 × 10 6 CD34 + cell/kg (median 7.8). Leukocyte and neutrophil recovery was accelerated by G-CSF administration at a dose of 300 g starting on the day after ASCT.
Patients with any residual mediastinal abnormality on CT scan (even if they had a negative Ga 67 scan) received mediastinal radiation therapy (RT) that was delivered 6 to 8 weeks after the end of treatment. RT was limited to original sites of involvement, with radiation doses ranging from 30 to 36 Gy over 4 to 5 weeks. 
Statistical analysis
Statistical analysis was performed according to the EBMT Statistical Guidelines. 24 Overall survival (OS) and event-free survival (EFS) were calculated according to the Kaplan-Meier method and plotted using JMP software (version 3.2.2, 1997; SAS Institute, Cary, NC, USA). All patients who underwent ASCT were referred to the EBMT registry.
Results

Low risk patients
The four patients in the low risk group achieved CR after VACOP-B. Two cases received consolidation radiotherapy. At a median follow-up of 30 months (range 24 to 84) all patients remained in continuous CR.
Intermediate-high/high risk patients
After induction CHT of the 15 poor risk patients, five were in CR, seven in PR and two had RD. All these patients underwent mobilising therapy with cyclophosphamide: those in CR received cyclophosphamide 4 g/m 2 , while the remaining 10 who had achieved only PR (seven patients) or who had RD (three patients) received 7 g/m 2 . After mobilising therapy, the seven patients in PR received further treatment with high-dose etoposide: two entered CR, and five remained in PR. Among the three patients with RD treated with two additional courses of DHAP, one obtained a PR. At the time of ASCT, seven patients were in CR, six in PR and two had RD. Disease status at ASCT is summarised in Figure 1 .
After transplantation, 14 out of the 15 patients achieved
Bone Marrow Transplantation CR defined as complete disappearance of all measurable disease (seven cases), or tumour mass reduction greater than 75% with Ga 67 scan negativity (seven cases). The seven patients in CR with a residual mediastinal abnormality after transplantation received additional RT as previously described. The single patient in PR after transplantation and RT died of MLCL progression 10 months after transplantation. At a median follow-up of 35 months from transplantation (range 10 to 90) the DFS is 93% (Figure 2 ).
Transplant-related toxicity
None of the 15 transplanted patients died within 100 days of completing high-dose chemotherapy. After BEAM chemotherapy all patients achieved complete haematologic recovery. The median time to reach an absolute granulocyte count greater than 0.5 × 10 9 /l was 9 days (range 8 to 14 days) and a self-sustaining platelet count Ͼ20 × 10 9 /l was reached after 9 days (range 7 to 17). The major nonhaematologic toxicity of this regimen was oral and gastrointestinal mucositis that led two patients to require continuous infusion of narcotics for pain control. Eight patients experienced an episode of fever (Ͼ38°C) and were treated with empirical intravenous broad-spectrum antibiotics: median duration of antibiotic administration was 9 days. Fever remained of unknown origin in seven cases while one patient developed sepsis secondary to Staphylococcus aureus.
Discussion
We report a single centre experience on 19 consecutive cases of primary MLCL with sclerosis. All patients received VACOP-B induction. The four low risk patients achieved a complete remission (CR). Of the 15 poor risk patients, five achieved CR, seven PR, and three had RD. After induction all poor risk patients received an early intensification programme including intensified CHT, ASCT, and RT in the event of residual mediastinal masses. In an attempt to obtain greater tumour mass reduction before transplantation, those with RD or who showed an incomplete response after VACOP-B were treated with further chemotherapy: with this approach we observed an additional clinical response in three out of 10 patients (two of seven patients in PR entered CR after high-dose etoposide and one of three patients with RD partially responded to DHAP) (Figure 1 ). After ASCT 14/15 (93%) poor risk patients are alive and disease-free at a median follow-up of 35 months from transplantation ( Figure 2 ).
In the setting of large cell lymphomas it is well recognised that patients in intermediate-high/high risk IPI groups have a poor outcome when treated with conventional chemotherapy. The application, however, of the IPI scoring system is still debated for MLCL. 25 A multicentre study of 106 patients specifically designed to identify prognostic factors for mediastinal lymphoma revealed that a poor performance status (PS) and a pericardial effusion (PE) at diagnosis were the two main independent factors associated with non-response and poor survival on multivariate analysis. 6 It is of note that poor PS and PE were present respectively in 100% and 60% of transplanted patients in our series, and this included 67% of patients (10/15) showing an incomplete response after VACOP-B. Taken together, all these factors (AA-IPI ϾI, substantial presence of pericardial effusions and incomplete response to induction chemotherapy) afford our patients a very poor prognosis and a disease-free survival of 93% is a very good result.
With the use of conventional chemotherapy (MACOP-B) and involved field fractionated RT as first line treatment for MLCL, Martelli et al 20 reported a 91% probability of progression-free survival (PFS); in that series, however, only 38% of 37 patients presented with bulky disease, 32% with poor PS, 11% with PE and 13.5% with stage III-IV. 20 These clinical features may be associated with a large proportion of low risk patients in whom an excellent response to conventional-dose chemotherapy is expected. By contrast, Bieri et al, 26 in a recent report on 27 cases of MLCL, obtained a PFS of 44% at 3 years with the use of a doxorubicin-containing regimen. In this experience a poorer OS was associated with age Ͼ60 years, intermediate-high to high risk category and PS ϾI. 26 The role of RT as consolidation treatment cannot be directly assessed from this study as all patients with a residual mediastinal mass on CT scanning were scheduled to be consolidated with RT, independently from Ga 67 scan results. Further prospective studies with PET are needed to better differentiate post-therapy fibrosis from residual disease and to select patient candidates for RT strictly.
Patients with MLCL have been reported to have low rates of bone marrow involvement, which makes them amenable for treatment strategies that include ASCT, with encouraging results.
6,14,19 Nademanee et al 19 described 13 patients with poor prognostic factors and a high or intermediate-high IPI risk who underwent ASCT in their first response: 12/13 remain alive and in remission with a median follow-up of 42 months (1 to 91). Sehn et al, 14 in a retrospective study of 35 patients, reported an estimated 5-year PFS rate of 83% for patients in their first response and, interestingly, a 58% and 27% of PFS for primary refractory and relapsed patients, respectively.
Our study also included two patients with resistance to VACOP-B, high-dose cyclophosphamide and DHAP chemotherapy. Both experienced CR after ASCT and RT with a follow-up of 16 and 28 months, respectively. Thus, it would appear that treatment intensification with ABMT in MLCL may result in a high response rate even in patients with resistant disease. In contrast, Philip et al 27 in refractory patients with aggressive lymphomas following transplantation, and Lazzarino et al 25 in refractory MLCL mainly treated with standard-dose chemotherapy, reported a 3-year PFS of 0%.
Our experience indicates that this front-line programme integrating standard induction CHT, intensified CHT, ASCT and RT in poor prognosis MLCL also results in a high incidence of durable remission in primarily refractory patients. The impact of this approach and the exact role of adjuvant RT in this context should be prospectively evaluated in a larger series of patients.
